Key Takeaways from the Alpha-Antitrypsin Deficiency Pipeline Report
-
Over 12+ companies and 12+ pipeline drugs in Complicated Urinary Tract Infections are in various stages of development, and their anticipated acceptance in the Complicated Urinary Tract Infections market would significantly increase market revenue.
-
Leading Complicated Urinary Tract Infections companies developing novel drug candidates to improve the Complicated Urinary Tract Infections treatment landscape include Spero Therapeutics, Iterum Therapeutics, and Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals and many others.
-
Promising Complicated Urinary Tract Infections pipeline therapies in various stages of development include VX-814 , ZF874, APB, and many others.
Complicated Urinary Tract Infections Overview
Urinary tract infections (UTI) are the most common bacterial infections involving lower (cystitis, prostatitis) or upper (pyelonephritis, renal abscess, perinephric abscess) urinary tract. Differentiation of complicated and uncomplicated UTI is usually based on the presence of structural or functional urinary tract abnormalities, which can increase the risk of treatment failure and development of serious complications. Factors that increase the risk are foreign bodies, stones, obstruction, neurogenic bladder, kidney transplantation, immunosuppression, and pregnancy. Complicated UTI includes a spectrum of conditions that increase the risk of treatment failure, as well as of serious complications such as bacteremia and sepsis, perinephric abscess, renal impairment and emphysematous pyelonephritis. A good quality urine specimen is vital in making the diagnosis. However, treatment must not be delayed if the clinical scenario is strongly suggestive of a urinary tract infection. Blood cultures are also useful in more severe septic presentations. A positive blood culture can sometimes also help corroborate a urine sample result and reduce the suspicion of contamination. Ultrasound and CT scans may sometimes be useful or even critical for diagnosing perinephric abscess, urinary retention, hydronephrosis and obstructive pyelonephritis from stones in septic patients. As UTI can present with severe, life-threatening sepsis and multiorgan involvement. Resuscitation often precedes definitive treatment. The severely septic patient might need aggressive fluid resuscitation as well as broad-spectrum antibiotics administered in the emergency department.
Complicated Urinary Tract Infections Pipeline Analysis: Drug Profile
Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
Spero Therapeutics is developing tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) as an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations (stay at home) and/or transition patients home after IV therapy (get home). In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI, including acute pyelonephritis (AP). ADAPT-PO is a landmark trial that is the first ever to test an all oral regimen against an all intravenous (IV) regimen for the treatment of cUTI. The global, randomized, placebo-controlled ADAPT-PO trial evaluated the safety and efficacy of tebipenem HBr in hospitalized adult patients with cUTI or AP. Data from the trial demonstrated that oral tebipenem HBr was statistically non-inferior to IV ertapenem in the treatment of patients with cUTI and patients with AP. If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP .Following feedback from the US FDA at Spero’s recent Type A meeting, Spero will conduct an additional phase III trial to support the regulatory submission.
Discover more about the emerging Complicated Urinary Tract Infections drugs @ Complicated Urinary Tract Infections Treatment Drugs
Complicated Urinary Tract Infections Pipeline Therapies and Key Companies
-
Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
-
Sulopenem: Iterum Therapeutics
And many others
Complicated Urinary Tract Infections Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
The complicated Urinary Tract Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Complicated Urinary Tract Infections Pipeline Report
-
Coverage: Global
-
Key Complicated Urinary Tract Infections Companies: Spero TherapeuticsIterum Therapeutics, Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals and many others
-
Key Complicated Urinary Tract Infections Pipeline Therapies: Tebipenem Pivoxil Hydrobromide, Sulopenem and many others
Find out more about the Complicated Urinary Tract Infections treatment options in development @ Complicated Urinary Tract Infections Clinical Trials
Table of Contents
1. Complicated Urinary Tract Infections Introduction
2. Complicated Urinary Tract Infections Executive Summary
3. Complicated Urinary Tract Infections Overview
4. Complicated Urinary Tract Infections Pipeline Therapeutics
5. Complicated Urinary Tract Infections Late-Stage Products (Phase III)
6. Complicated Urinary Tract Infections Mid-Stage Products (Phase II)
7. Complicated Urinary Tract Infections Early Stage Products (Phase I/II)
8. Complicated Urinary Tract Infections Preclinical Stage Products
9. Complicated Urinary Tract Infections Discovery Stage Products
10. Complicated Urinary Tract Infections Therapeutic Assessment
11. Complicated Urinary Tract Infections Inactive Products
12. Complicated Urinary Tract Infections Collaborations Assessment- Licensing / Partnering / Funding
13. Complicated Urinary Tract Infections Unmet Needs
14. Complicated Urinary Tract Infections Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services